Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/hemoshear-therapeutics-to-participate-in-svb-leerink-securities-biopharma-private-company-connect-301650935.html
https://www.prnewswire.com/news-releases/hemoshear-develops-new-human-tissue-based-model-of-rare-liver-disease-under-research-collaboration-with-takeda-301602822.html
https://www.prnewswire.com/news-releases/hemoshear-therapeutics-identifies-second-novel-target-to-treat-nash-through-successful-collaboration-with-takeda-301424799.html
https://www.prnewswire.com/news-releases/hemoshear-therapeutics-advancing-several-novel-compounds-for-horizon-therapeutics-plc-gout-discovery-pipeline-301380995.html
https://www.biospace.com/article/releases/hemoshear-therapeutics-raises-40-million-in-series-a-financing-to-advance-rare-disease-portfolio/
https://www.prnewswire.com/news-releases/hemoshear-therapeutics-hst5040-receives-us-orphan-drug-designations-for-treatment-of-methylmalonic-acidemia-and-propionic-acidemia-301193648.html
https://www.prnewswire.com/news-releases/hemoshear-therapeutics-identifies-novel-drug-target-to-treat-nash-in-drug-discovery-partnership-with-takeda-301189996.html
https://www.prnewswire.com/news-releases/hemoshear-therapeutics-enters-into-rare-liver-disease-research-collaboration-with-takeda-301157045.html
https://www.prnewswire.com/news-releases/hemoshear-therapeutics-receives-fda-fast-track-and-rare-pediatric-disease-designations-for-hst5040-to-treat-methylmalonic-acidemia-and-propionic-acidemia-301100714.html
https://www.prnewswire.com/news-releases/hemoshear-therapeutics-receives-fda-fast-track-and-rare-pediatric-disease-designations-for-hst5040-to-treat-methylmalonic-acidemia-and-propionic-acidemia-301100714.html